These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21208905)

  • 1. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
    Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
    Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative lengthening of telomeres in human glioma stem cells.
    Silvestre DC; Pineda JR; Hoffschir F; Studler JM; Mouthon MA; Pflumio F; Junier MP; Chneiweiss H; Boussin FD
    Stem Cells; 2011 Mar; 29(3):440-51. PubMed ID: 21425407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomeres, senescence, and hematopoietic stem cells.
    Zimmermann S; Martens UM
    Cell Tissue Res; 2008 Jan; 331(1):79-90. PubMed ID: 17960423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting of neural cancer stem cells: TTAGGG, you're it!
    Hjelmeland AB; Rich JN
    Clin Cancer Res; 2011 Jan; 17(1):3-5. PubMed ID: 21208901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
    Chen Z; Koeneman KS; Corey DR
    Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
    Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR
    Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
    Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
    Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
    Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
    Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
    Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
    Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.
    Brachner A; Sasgary S; Pirker C; Rodgarkia C; Mikula M; Mikulits W; Bergmeister H; Setinek U; Wieser M; Chin SF; Caldas C; Micksche M; Cerni C; Berger W
    Cancer Res; 2006 Apr; 66(7):3584-92. PubMed ID: 16585183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoplastic transformation by TERT in FGF-2-expanded human mesenchymal stem cells.
    Yamaoka E; Hiyama E; Sotomaru Y; Onitake Y; Fukuba I; Sudo T; Sueda T; Hiyama K
    Int J Oncol; 2011 Jul; 39(1):5-11. PubMed ID: 21573488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.
    Brennan SK; Wang Q; Tressler R; Harley C; Go N; Bassett E; Huff CA; Jones RJ; Matsui W
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.
    Binz N; Shalaby T; Rivera P; Shin-ya K; Grotzer MA
    Eur J Cancer; 2005 Dec; 41(18):2873-81. PubMed ID: 16253503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.